Ramsay Health Care Limited (RHC) Earnings Call Transcript & Summary

November 6, 2026

Australian Securities Exchange AU Health Care Health Care Providers and Services earnings 29 min

Earnings Call Speaker Segments

Pascal Roche

executive
#1

Alright, thank you very much. And thanks to everyone for being on this Q1 Ramsay Sante call. So today, as was just mentioned, we'll be walking through the results that we released yesterday evening, and I'm joined by Clement Lafaix, our Group CFO. Moving into these Q1 results on Page #4, if we had to sum things up in just a few seconds, we'd say we delivered a solid Q1, with revenue continuing to grow and operational performance improving. In fact, revenue came in at EUR 1.233 billion, up 2.9% compared with the same quarter a year ago. On a constant currency basis, that would be growth of 2.6% — and what's behind it? Higher MSO activity has been the driver. To give you one example, in France MSO admissions rose by 4.1%, with targeted efforts producing a big jump in day medicine development in France, plus continued strength in the Nordic region. But beyond that growth, we're glad to report that Q1 EBITDA came in at EUR 121 million against EUR 112 million a year earlier, a 9.8% margin. Do bear in mind this is Q1, with the seasonal impact of July and August; so profitability improved, driven not only by that revenue growth but also by productivity gains, disciplined cost control across every geography and, as you'll remember, the ongoing execution of the St. Goran contract, despite all the tariff headwinds. On top of that, the leverage ratio is down compared with Q1 last year, with continued deleveraging of 0.2 points. We'll return to this later with Clement Lafaix; so in this context, at Ramsay Sante we have maintained our short-term and midterm financial outlook. Also on this slide — #4, by the way — there was a significant business development last quarter: very old litigation, I'd say, dating back to 2002, 2004, concerning one very important hospital in Lyon named Jean Mermoz. An appeal ruling came down, and it confirmed that the group bears no liability on the matter of the building from more than 20 years ago; that means EUR 57 million in damages remains to be received under the decision, subject to any further appeal by the opposing party, I'd say our opponent. That said, if we move to the next page: at the Capital Market Day we held on September 17, we shared our ambition for the years ahead through 2030, our strategic plan, connecting care 2030, to unlock the full potential of integrated care along with reinforcement of active portfolio management and efficiency measures. So we're pleased to share a few deliveries that happened during Q1 across the 5 avenues. To further reinforce the integrated care offering, in Sweden the referral from a very large central hospital to discharge patients into advanced home care, inpatient palliative care, and inpatient rehabilitation. So the count of patients proposed at discharge because they required follow-up by one of a business unit, one of our team, has risen by 70% versus Q1 2024, so 2 years ago. Speaking of again accelerating the additional profitable growth through new revenue stream, glad to share that on imaging for France last month, we have been deploying 2 new units, one PET scan and radiotherapy, by the way, at the Peupliers hospital in Paris. On the third pillar, digitalization and AI, we continue rolling at full speed on the rollout of NB scripts; so speech to text to release, let's say, the administrative burden and free up some patient time for the doctor. It is completed for all the Primerica in Sweden. And now we are picking up the pace in the mental health business unit in France and with our own AI Ramsay companion tool, it again checks the box of better medical excellence and better efficiency. For instance, Ramsay Companion there is over 100 per month in September, a couple of days ago. On portfolio management, we committed during the CMD to say that in venue South of France, will go from 3 facilities to 1 facility, cutting, by the way, the number of beds by roughly 50 beds, delivering additional EBITDA; it has been completed as planned on October 1. And lastly, on the continued cost optimization initiative, the choosing wisely, which is better for the patient and efficiency is rolling out again across various country; and 3 weeks ago, we have been relocating the group headquarter; we used to be in Paris; we are now in the suburb of Paris and with a good — let's say, a good setting. Another update to share on the next slide, during again, the CMD mid-September regarding the new Board, again, would the demerger take place and would the Ramsay Sante AGM on December 4 validate this content, new governance framework we were saying. Again, we confirm that the majority of the Board will be made up of independent director through a very rigorous process. The Chairman of the Board will be independent. I'm going to return to this in a couple of seconds. The Chairman of the Audit Committee will be independent and all this refers to the Afep-Medef French Governance Code. Speaking of the Chairman will be proposed, by the way, to the Ramsay Sante AGM, Frederic Collet, Independent Chairman of the Board. Frederic Collet brings extensive, extensive experience in the health care sector in France and internationally. He served as Chairman of Novartis France and worked at Sandoz as Head of Oncology worldwide. Incidentally, for 4 years in France, he was Chairman of the Association of the French pharmaceutical industry; and by the way, for a couple of years he has sat on the Board of the Institute Imagine, the biggest institute for genetic disease in France, a key institute, I would say. He is well acquainted with Ramsay Sante because, as you know, we are a mission-driven company. He has taken part over the last 3 years in this committee and is, by the way, both Founder and President of BIOnnassay-Consult, Senior Adviser at Eurazeo and Chairman of AI and Cancer Consortium; so this is the key news in a nutshell I wanted to share with you to give more granularity regarding the financial performance during the last 3 months. I'm giving the floor to Clement.

Clement Lafaix

executive
#2

Thanks, Pascal. Good morning and good afternoon, everyone. Before we move to the next slide, I'd like to restate the main point: our top line has held up well, and the increase is mostly a matter of higher volumes. Over the past quarter, underlying profitability has risen faster than revenues, which reflects our performance plans even with tariffs posing constraints, and we're still bringing down the company's debt; let's turn to Page #8. Now let's take a closer look at a few numbers. Revenue was up 2.9% in the last quarter, or 2.6% when measured at constant FX, with gains across every geography and every segment of activity. As this bridge shows, all of that growth came from organic sources. In France, organic revenue growth stayed resilient at 2.2%, with no tariff increase, backed by a 4.1% rise in MSO volumes. Day medicine gave notable support, growing quite substantially—roughly plus 40%—during the last quarter; the continued negative mix effect from a shift out of full hospitalization into ambulatory care partly offset this. In the Nordics, organic growth came in at 4.2%, driven by primary care development, St. Goran's robust volume, and the new contract's effect. Moving to the next page, let's examine our profitability. Over the past quarter, EBITDA rose 7.5% compared with a year earlier, and it was also up EUR 8 million in absolute terms, even as inflation climbed—especially in France, where the minimum wage went up 2.4% in June '26. That inflation isn't offset by the tariff, particularly in France. So how did we manage this gain in profitability? Organic growth—I've already mentioned it—along with St. Goran's new contracts in Q1, and we anticipate an additional impact in Q2, since this contract will only begin counting on a like-for-like basis starting in January of next year. I also referred to the structural performance plan and our cost containment initiatives. Obviously, to steer through a tariff situation that is restricted, strong performance and operational execution matter most. Let me share a few illustrations of what was achieved on that front during the quarter. To begin with, as we noted, the imaging units — the two new imaging units — so we keep gaining speed there. I also brought up day medicine care, which is expanding at a very rapid rate, along with additional gains in coding accuracy through AI and a cut in nonmedical staff in France during the last quarter. In the Nordics, we achieved strong cost containment in pharma and primary care, using benchmarking across units and greater reliance on generics—something Pascal brought up. We also advanced nicely on portfolio management, transferring the operations of the Valence unit along with a maternity ward transfer; that's not the end of it. We've already pinpointed further actions, and those will keep ramping up. Turning to the next page on leverage—September usually shows higher leverage than June, reflecting normal seasonality in the business. Over the summer holidays, patients aren't getting nonemergency care. Yet if you look at September versus the same month a year earlier and two years back, as the chart illustrates, we continue to bring down the company's leverage — down 0.2% across the past three years — on the strength of EBITDA generation and better operational cash flow. During the most recent quarter we saw a favorable working capital change, since the prior year's figure took a negative hit from repayment of French state advances, which did not occur this time around. We're still focused on the French DSO to cut down our delays, and we've paired that with a selective approach to CapEx — growth CapEx came in at 4% of revenues this quarter, unchanged from a year ago, with spending clearly weighted toward high investments and strategic priorities; that means we keep building out imaging radiotherapy, and we also steer CapEx toward portfolio management initiatives. Turning to financing, there's a major item from this quarter. In July 2026, we should of course note that the refinancing of our senior debt is now complete — EUR 1.75 billion, which includes a EUR 200 million RCF left undrawn; maturities on that senior debt now stretch to 2033, and we've streamlined our balance sheet structures too, which gives us greater flexibility. In addition, we refinanced the real estate on HP Dijon-Bourgogne in France, pulling a fresh tranche under a Fiducie structured loan. This shows how property can serve as a route to solid financing on appealing terms. Perhaps one final note on our hedging approach, given that we are seeing interest rates climb. We take a proactive stance and continuously optimize our hedging strategy. At present, 80% of our gross financial debt is hedged once more, against the backdrop of rising rates. To wrap up, a solid beginning to the year, in terms of our capacity to lock in organic growth and turn it into financial results, as well as to delever. Turning to what matters most in the coming months: first, execution — apologies, let's go to the next page, Page 12, that's right — carrying out the performance plan is plainly a top priority, along with delivering the new strategy and keeping top line growth going, particularly by drawing on our integrated health care offering, upholding high standards of care, and improving medical outcomes. Together with strict capital allocation, all of this will help deleverage the company. As Pascal announced — moving to Page 13 — we are maintaining and confirming our guidance for both the short and the midterm. For FY '27, revenue growth of 2% to 3% at constant FX, with a stable EBITDA margin compared with last year. Looking ahead to fiscal 2029, we expect yearly top-line expansion of roughly 3% compounded, with EBITDA margins strengthening steadily, growth capital expenditures averaging about 4% of sales across the coming three years, and ongoing debt reduction aimed at bringing net debt to pre-IFRS EBITDA under 4.0. Thanks for joining us. Pascal and I are happy to take any questions you might have.

Pascal Roche

executive
#3

All right, thank you, Clement. And so, as was just mentioned, please don't hesitate to ask whatever questions you might have.

Craig Wong-Pan

analyst
#4

I’d like to ask about net debt. I get that the leverage ratio normally rises between June and September because of seasonality, but if you look just at the net debt number, it went up by roughly EUR 145 million from June to September as well. Could you explain the reason for that increase?

Pascal Roche

executive
#5

Yes, of course. Thanks for asking. I think that in comparing with June, we need to take into account how seasonality affects our activities. We traditionally know that during the first quarter of the year — so we have 2 months, 2 summer months, when patients don’t undergo particular nonemergency surgeries, I would say, that are needed — so we know activity is lower; therefore, in our first quarter of the year, net debt usually goes up compared with June. But again, we have to compare September with September. That’s why we showed this view, I think, on Page #11 of the presentation, which shows — Page 10, sorry, which shows a lower level of net debt compared with last year and compared with 2 years ago; so again, seasonality is the correct explanation for your question, I think.

Clement Lafaix

executive
#6

While we wait for some questions, perhaps—we've received a few written questions, so maybe we can address some of them. One question asks how we explain that despite admission growth in France of 4.1%, revenue growth is somewhat lower—which is true, by the way; we're more in the range of 2.4%. Well, I'd say there are two reasons. The first is the activity mix. Surgery keeps increasing versus inpatient. Just to remind you that over the last 12 years, regarding surgery for Ramsay Sante in France, we've grown from 49% day surgery to 74% day surgery, which means that today, for many, many surgeries, the patient leaves the hospital the same day, whereas 12 years ago, he would spend maybe 1 or 2 nights in the hospital; and in short, day surgery on average is paid less than inpatient surgery; so there's this activity mix value, which is the first driver. The second driver is that tariffs have been very constrained, even decreasing, by the way, in some specialties such as imaging. So these 2 factors combined explain, if I may, why MSO admissions for France of 4.1% don't translate exactly into 4.1% revenue growth. There's another—by the way, there are a couple of similar questions regarding day medicine for France, just to explain what it is. Day medicine has been promoted, I'd say, approved by the French government in order to initiate a same-day pathway. So there are many day medicine pathways, e.g. obesity, e.g. pain management, et cetera, et cetera. And if you see the right 4 specialists, the same day can be a doctor, a physio, et cetera, et cetera. But as long as you see the 4 specialists the same day in the same unit, you're paid, I'd say, at a better price, a much better price. So it's a huge need from a patient standpoint, and it has, I'd say, a very positive economic impact for the company; so yes, we're running—we're growing, I'd say, in this specific segment, not double digit, but really in the range of 35% to 40%. We have a next question regarding cost initiatives. Elaborate on these initiatives? And should we expect nonrecurring costs for those initiatives? So we will turn every stone clearly behind the different lines of the P&L; but clearly, we're working on every caption, I'd say, of the cost—be it personnel cost, adapting actual staffing to activity, reducing temp staff, reducing nonmedical staff as well, increasing our productivity. On the medical purchasing side, we've got a few initiatives as well aimed at centralizing things and making sure we get the best cost per reference—working in particular with doctors in France to bring down the number of references while enhancing and improving our purchasing terms. Under the performance initiatives, it's not just cost—we also have some mix improvement efforts tied to coding accuracy. You brought up Pascal, and that's clearly another route to improving our mix from a margin standpoint, since we see these kinds of pathways as benefiting our margins. So alongside the performance plans, there are also the portfolio management initiatives, which, as you know, form a very significant piece of the Connecting Care 2030 strategic plan. With that portfolio management, we may incur a few nonrecurring costs to put these measures in place, but we expect those costs to stay fairly limited, because essentially it's about optimizing our portfolio and—again—trimming the footprint wherever we can and moving faster in the segments that are more profitable.

Pascal Roche

executive
#7

Yes. Thank you, Clement. We've received 4, maybe even 5, questions about next year's French budget and the healthcare budget. What I can tell you is that, as of today, France has an overall budget plus uncertainty. The dedicated 2027 healthcare budget for France, known as the PLFSS, was rejected 2 days ago, by the way, so it now goes back to parliament. First, on Ramsay Sante, naturally we don't speculate on political outcomes, I'd say. But we don't know, and nobody knows. That said, by definition we are always actively engaged with the healthcare authority and policymakers, I'd say, to advocate and simply to remind them that private healthcare providers in France form a systemic backbone of the French system. Now I think it's worth sharing with you once again, as we did during the CMD, that Ramsay Sante's outlook doesn't depend only, I'd say, on tariff support — we have multiple levers at our disposal, I'd say, under management control: volumes, capacity utilization, procurement, workforce management and productivity, beyond of course the fact that outside France, other countries now account for 1/3 of total activity, with at least clear visibility here. So we don't know. That's the short answer. But once again, we are focused on what is in our hands, I'd say.

Clement Lafaix

executive
#8

There's a particular question about CapEx being 4% of our revenues. Does that figure cover greenfield? Or does it only reflect maintenance CapEx? Well, 4% represents total gross CapEx prior to the leasing arrangements we put in place to finance, in particular, the imaging equipment. So that 4% growth CapEx is the overall figure, keeping in mind that roughly 3% relates to maintenance, IT and regulatory, while 1% on average goes toward development — and it's precisely this development CapEx pocket that we'll allocate to our strategic priorities. We also have a question about real estate. How much do we actually own? And how much debt is tied to that real estate? As we covered during the CMD, real estate was valued at EUR 1.5 billion as of the end of June. That accounts for 20% of the square meters we operate across the group, situated in France, with 2 half of it in prime locations like the Paris region. And through this real estate, we've managed to draw approximately EUR 350 million of real estate debt, an amount that rose slightly by the end of September to roughly EUR 400 million following the refinancing of HP Dijon Bourgogne, which I referenced earlier in this presentation.

Pascal Roche

executive
#9

All right. Thank you, Clement. Are there any further questions?

Pascal Roche

executive
#10

Fine. Many thanks. So my sense is that we've made an effort to address the written questions that came in. At least, I hope that's the case, together with Clement. Well, thank you again for joining us this morning for our Q1 results. And as I always say, we remain available to you. Should you have any particular questions, we'll do our utmost to respond. Thanks again, and have a great day. Bye-bye.

Clement Lafaix

executive
#11

Thank you.

Operator

operator
#12

Thanks. That brings us to the end of today's conference call. We appreciate everyone joining us, and you're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ramsay Health Care Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Ramsay Health Care Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Ramsay Health Care Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.